This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
R&D partnering vision
|
Our vision is to drive innovation through healthy and productive alliances. We have the skills and experience within drug and device development to turn your ideas into treatment solutions for patients. We leverage our protein expertise to develop life-changing treatments for people living with chronic diseases. Learn more about partnering with Novo Nordisk Download our partnering for innovation brochure |
 |
Diabetes
Novo Nordisk has been a leader in diabetes care since 1923 and continues to pioneer the development of novel treatments for this serious condition. We are constantly striving to improve the lives of people with diabetes by finding better methods of diabetes treatment and prevention.
Haemophilia
Our ambition is to change possibilities for people with haemophilia. Every step of our journey is focused on improving treatment options, providing better access to care and following through on our commitment to understand the needs of people with haemophilia.
Autoimmune inflammatory disorders
Our ambition is to develop novel immunotherapies that will significantly improve the lives of people with autoimmune and chronic inflammatory diseases such as rheumatoid arthritis, lupus, inflammatory bowel disease, and psoriatic arthritis. We have a number of innovative monoclonal antibody projects in early clinical development.
Growth disorders
Novo Nordisk has been a major player in the field of growth hormone therapy for many decades. We keep exploring new modalities to treat human growth hormone disorders.
Protein delivery
|
In 1985, Novo Nordisk introduced the world’s first insulin pen. Since then, we have made extensive efforts in R&D of new delivery systems to help people with chronic diseases manage their treatment. Our partnering focus within protein delivery |
 |
Novo Nordisk and INSERM collaborate to find novel treatments for haemophilia patients
|
Novo Nordisk and INSERM, France's only public research institute dedicated solely to human health, have a research partnership to pursue novel biologics in haemophilia. |
Diabetes Innovation Award Program
We are supporting scientists and academic research institutions in the US and Canada.
Our focus is protein-based therapeutics and technologies for diabetes and obesity.
Meet us at partnering events around the world
We are attending international events throughout the year to meet with new potential partners. Take a look at our event calendar to see when and where we will be this year.
Our teams
Strategic Sourcing in Diabetes & Obesity is focusing on opportunities in diabetes, protein technologies and protein delivery devices.
Biopharmaceuticals Innovation Sourcing is focusing on opportunities in haemophilia, inflammation and growth disorders.
